ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for CRNX

Stock NameCrinetics Pharmaceuticals Inc
TickerCRNX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS22663K1079
LEI549300Q1CNFXK5P31D28

Show aggregate CRNX holdings

News associated with CRNX

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $68.86 Consensus Price Target from Brokerages
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective […] - 2025-08-19 02:16:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Cut to $86.00 by Analysts at JMP Securities
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price reduced by JMP Securities from $90.00 to $86.00 in a report published on Monday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Several other research firms have also recently weighed in on CRNX. HC Wainwright reaffirmed a “buy” rating and set […] - 2025-08-12 04:47:05
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Victory Capital Management Inc.
Victory Capital Management Inc. lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 10.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 251,331 shares of the company’s stock after selling 30,120 shares during the quarter. Victory Capital Management Inc.’s holdings in […] - 2025-07-25 06:06:53
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price […] - 2025-07-22 07:55:07
New York State Common Retirement Fund Sells 17,508 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
New York State Common Retirement Fund lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 11.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 137,918 shares of the company’s stock after selling 17,508 shares during the quarter. New York State Common […] - 2025-07-22 07:13:05
Teacher Retirement System of Texas Decreases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Teacher Retirement System of Texas decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 6.5% in the 1st quarter, Holdings Channel reports. The fund owned 22,442 shares of the company’s stock after selling 1,561 shares during the quarter. Teacher Retirement System of Texas’ holdings in Crinetics Pharmaceuticals were worth $753,000 […] - 2025-07-15 04:24:35
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year […] - 2025-07-02 04:30:55
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $3,141,877.09 in Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Stephen F. Betz sold 97,483 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $32.23, for a total transaction of $3,141,877.09. Following the transaction, the insider now owns 99,713 shares of the company’s stock, valued […] - 2025-06-19 05:10:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Mackenzie Financial Corp
Mackenzie Financial Corp grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,422 shares of the company’s stock after purchasing an additional 440 shares during the period. Mackenzie Financial Corp’s holdings […] - 2025-06-05 06:18:55
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have received an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 […] - 2025-06-02 02:10:52
State of Wyoming Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
State of Wyoming purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 985 shares of the company’s stock, valued at approximately $50,000. Several other large investors […] - 2025-05-30 05:06:48
Bank of America Corp DE Cuts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Bank of America Corp DE decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 15.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 235,281 shares of the company’s stock after selling 42,792 shares during the period. Bank of America Corp DE’s holdings in Crinetics Pharmaceuticals were worth $12,030,000 […] - 2025-05-23 06:26:56
BNP Paribas Financial Markets Sells 5,683 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
BNP Paribas Financial Markets decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 27.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,259 shares of the company’s stock after selling 5,683 shares during the period. BNP Paribas Financial Markets’ holdings in Crinetics Pharmaceuticals were worth $780,000 at the […] - 2025-05-23 04:58:51
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 6,719 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,163 shares of the company’s stock after acquiring an additional 6,719 shares during […] - 2025-05-21 05:40:53
Ameriprise Financial Inc. Has $18.16 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Ameriprise Financial Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 110.8% during the fourth quarter, Holdings Channel reports. The fund owned 355,174 shares of the company’s stock after buying an additional 186,681 shares during the quarter. Ameriprise Financial Inc.’s holdings in Crinetics Pharmaceuticals were worth $18,159,000 as of […] - 2025-05-16 05:03:19
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year target […] - 2025-05-08 02:22:53
Envestnet Asset Management Inc. Buys 8,751 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Envestnet Asset Management Inc. boosted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.1% during the 4th quarter, HoldingsChannel reports. The fund owned 63,077 shares of the company’s stock after buying an additional 8,751 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Crinetics Pharmaceuticals were worth $3,225,000 as […] - 2025-04-25 04:24:46
Legal & General Group Plc Buys 12,538 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Legal & General Group Plc lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 88,939 shares of the company’s stock after acquiring an additional 12,538 shares during the quarter. Legal & General Group Plc’s holdings in Crinetics Pharmaceuticals were worth $4,547,000 as […] - 2025-04-22 04:47:14
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account. Representative Josh […] - 2025-04-14 03:02:59
Corebridge Financial Inc. Buys 1,992 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Corebridge Financial Inc. boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,599 shares of the company’s stock after buying an additional 1,992 shares during the period. Corebridge Financial Inc.’s holdings […] - 2025-04-02 06:46:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 44.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,089,391 shares of the company’s stock after acquiring an additional 2,801,736 shares during the quarter. Vanguard Group […] - 2025-04-02 05:24:53
16,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by KLP Kapitalforvaltning AS
KLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,000 shares of the company’s stock, valued at approximately $818,000. A number of other hedge funds have also added to […] - 2025-04-01 05:14:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Stifel Nicolaus
Analysts at Stifel Nicolaus began coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 73.86% from the stock’s previous close. […] - 2025-03-27 04:00:59
Arizona State Retirement System Grows Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Arizona State Retirement System boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,469 shares of the company’s stock after purchasing an additional 4,168 shares during the […] - 2025-03-14 06:10:48
Assetmark Inc. Purchases 1,014 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Assetmark Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,161 shares of the company’s stock after acquiring an additional 1,014 shares during the quarter. Assetmark Inc.’s holdings in Crinetics Pharmaceuticals […] - 2025-03-12 06:11:03
Keybank National Association OH Has $478,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Keybank National Association OH boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 9,352 shares of the company’s stock after purchasing an additional 1,176 shares during the quarter. Keybank National Association OH’s holdings in Crinetics Pharmaceuticals were worth $478,000 at […] - 2025-03-10 05:54:54
Handelsbanken Fonder AB Buys 2,800 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Handelsbanken Fonder AB raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 21,800 shares of the company’s stock after purchasing an additional 2,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Crinetics Pharmaceuticals were worth $1,115,000 at the end […] - 2025-02-28 07:25:04
New York State Common Retirement Fund Purchases 7,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
New York State Common Retirement Fund lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 155,426 shares of the company’s stock after purchasing an additional 7,735 shares during the quarter. New York State Common Retirement Fund’s holdings in Crinetics […] - 2025-02-27 06:51:01
Add Up The Pieces: VBK Could Be Worth $335
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-02-13 13:24:24
TD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)
Analysts at TD Cowen started coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating on the stock. CRNX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in […] - 2025-02-13 08:26:44

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) CRNX holdings

DateNumber of CRNX Shares HeldBase Market Value of CRNX SharesLocal Market Value of CRNX SharesChange in CRNX Shares HeldChange in CRNX Base ValueCurrent Price per CRNX Share HeldPrevious Price per CRNX Share Held
2025-12-17 (Wednesday)69,980CRNX holding decreased by -795USD 3,337,346CRNX holding decreased by -103027USD 3,337,346-795USD -103,027 USD 47.69 USD 48.61
2025-12-16 (Tuesday)70,775CRNX holding decreased by -159USD 3,440,373CRNX holding decreased by -58092USD 3,440,373-159USD -58,092 USD 48.61 USD 49.32
2025-12-15 (Monday)70,934CRNX holding increased by 318USD 3,498,465CRNX holding decreased by -66937USD 3,498,465318USD -66,937 USD 49.32 USD 50.49
2025-12-12 (Friday)70,616USD 3,565,402CRNX holding increased by 83327USD 3,565,4020USD 83,327 USD 50.49 USD 49.31
2025-12-11 (Thursday)70,616CRNX holding increased by 1265USD 3,482,075CRNX holding increased by 149066USD 3,482,0751,265USD 149,066 USD 49.31 USD 48.06
2025-12-10 (Wednesday)69,351USD 3,333,009CRNX holding increased by 11096USD 3,333,0090USD 11,096 USD 48.06 USD 47.9
2025-12-09 (Tuesday)69,351USD 3,321,913CRNX holding increased by 34676USD 3,321,9130USD 34,676 USD 47.9 USD 47.4
2025-12-08 (Monday)69,351USD 3,287,237CRNX holding increased by 50626USD 3,287,2370USD 50,626 USD 47.4 USD 46.67
2025-12-05 (Friday)69,351USD 3,236,611CRNX holding decreased by -52013USD 3,236,6110USD -52,013 USD 46.67 USD 47.42
2025-12-04 (Thursday)69,351CRNX holding increased by 3140USD 3,288,624CRNX holding increased by 178031USD 3,288,6243,140USD 178,031 USD 47.42 USD 46.98
2025-12-03 (Wednesday)66,211USD 3,110,593CRNX holding increased by 130436USD 3,110,5930USD 130,436 USD 46.98 USD 45.01
2025-12-02 (Tuesday)66,211CRNX holding increased by 2355USD 2,980,157CRNX holding increased by 90673USD 2,980,1572,355USD 90,673 USD 45.01 USD 45.25
2025-12-01 (Monday)63,856USD 2,889,484CRNX holding decreased by -19795USD 2,889,4840USD -19,795 USD 45.25 USD 45.56
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of CRNX by Blackrock for IE00BYXG2H39

Show aggregate share trades of CRNX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-17SELL-79549.04047.610 47.753USD -37,964 39.11 Loss of -6,868 on sale
2025-12-16SELL-15950.19048.380 48.561USD -7,721 39.07 Loss of -1,509 on sale
2025-12-15BUY31850.93049.280 49.445USD 15,724 39.03
2025-12-11BUY1,26550.07548.190 48.378USD 61,199 38.93
2025-12-04BUY3,140 47.420* 38.73
2025-12-02BUY2,35546.04044.595 44.740USD 105,362 38.66
2025-11-28BUY15746.82045.000 45.182USD 7,094 38.60
2025-11-26BUY47146.40044.500 44.690USD 21,049 38.53
2025-11-26BUY47146.40044.500 44.690USD 21,049 38.53
2025-11-25BUY78545.04043.070 43.267USD 33,965 38.50
2025-11-24BUY15744.86343.090 43.267USD 6,793 38.47
2025-11-20SELL-62845.15541.720 42.064USD -26,416 38.44 Loss of -2,278 on sale
2025-11-19BUY15743.56542.170 42.309USD 6,643 38.41
2025-11-18BUY94243.97542.280 42.449USD 39,987 38.39
2025-11-17BUY31444.36041.962 42.202USD 13,251 38.37
2025-11-14BUY15743.94740.975 41.272USD 6,480 38.35
2025-11-12BUY15743.48042.050 42.193USD 6,624 38.31
2025-11-10BUY15641.56039.890 40.057USD 6,249 38.27
2025-11-06BUY15643.89042.380 42.531USD 6,635 38.23
2025-11-04BUY15742.78041.510 41.637USD 6,537 38.19
2025-10-30BUY78544.69542.350 42.585USD 33,429 38.11
2025-10-29BUY31442.90043.855 43.759USD 13,740 38.09
2025-10-22SELL-62840.43042.720 42.491USD -26,684 37.99 Loss of -2,825 on sale
2025-10-20BUY31442.45042.810 42.774USD 13,431 37.94
2025-10-17BUY78441.57042.795 42.672USD 33,455 37.92
2025-10-15BUY1,24844.15045.960 45.779USD 57,132 37.89
2025-10-03BUY1,08540.86042.010 41.895USD 45,456 37.84
2025-10-02BUY15541.51042.177 42.110USD 6,527 37.82
2025-09-30BUY31041.65043.480 43.297USD 13,422 37.77
2025-09-29BUY31043.51047.410 47.020USD 14,576 37.74
2025-09-25BUY31035.89036.871 36.773USD 11,400 37.70
2025-09-24SELL-2,64435.18036.310 36.197USD -95,705 37.72 Profit of 4,024 on sale
2025-09-18BUY16335.48035.745 35.718USD 5,822 37.73
2025-09-17BUY48934.20035.090 35.001USD 17,115 37.75
2025-08-20SELL-65229.09029.640 29.585USD -19,289 37.92 Profit of 5,432 on sale
2025-07-30BUY65229.23030.150 30.058USD 19,598 38.24
2025-07-17SELL-32633.02033.280 33.254USD -10,841 38.68 Profit of 1,768 on sale
2025-07-16BUY84031.90032.670 32.593USD 27,378 38.72
2025-07-11SELL-1,28031.93032.210 32.182USD -41,193 38.85 Profit of 8,541 on sale
2025-07-07BUY48029.06030.343 30.215USD 14,503 39.08
2025-07-02BUY8,80029.44030.010 29.953USD 263,586 39.21
2025-06-20BUY1,66130.16030.860 30.790USD 51,142 39.28
2025-06-11BUY31032.33033.350 33.248USD 10,307 39.69
2025-06-10BUY31033.08033.770 33.701USD 10,447 39.74
2025-06-04SELL-15532.13032.650 32.598USD -5,053 39.97 Profit of 1,143 on sale
2025-04-23BUY15532.37032.890 32.838USD 5,090 42.50
2025-04-10SELL-1,24026.85027.170 27.138USD -33,651 43.78 Profit of 20,639 on sale
2025-04-08SELL-15525.56027.273 27.102USD -4,201 44.17 Profit of 2,646 on sale
2025-04-07SELL-15526.38027.230 27.145USD -4,207 44.38 Profit of 2,671 on sale
2025-04-04SELL-77526.89028.535 28.370USD -21,987 44.58 Profit of 12,563 on sale
2025-04-01BUY1,35630.62033.420 33.140USD 44,938 44.90
2025-03-31SELL-45933.54034.545 34.444USD -15,810 45.04 Profit of 4,864 on sale
2025-03-21BUY2,15034.42035.290 35.203USD 75,686 45.83
2025-03-14SELL-2,33634.47035.630 35.514USD -82,961 46.61 Profit of 25,921 on sale
2025-03-07SELL-29233.28034.145 34.059USD -9,945 47.53 Profit of 3,932 on sale
2025-03-04SELL-14634.06034.750 34.681USD -5,063 48.16 Profit of 1,968 on sale
2025-02-25BUY29232.30034.795 34.545USD 10,087 49.39
2025-02-19SELL-14536.60036.740 36.726USD -5,325 50.34 Profit of 1,974 on sale
2025-02-13BUY43535.26035.850 35.791USD 15,569 51.52
2025-02-12BUY14535.21035.220 35.219USD 5,107 51.84
2025-02-11BUY58034.93036.660 36.487USD 21,162 52.19
2024-12-30BUY1,66750.67051.280 51.219USD 85,382 57.35
2024-11-18SELL-2,05553.70055.050 54.915USD -112,850 58.02 Profit of 6,378 on sale
2024-11-08SELL-13760.69060.930 60.906USD -8,344 57.77 Loss of -429 on sale
2024-10-21SELL-13758.70058.880 58.862USD -8,064 0.00 Loss of -8,064 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of CRNX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19291,81110422,19069.1%
2025-09-18255,3114,887441,31757.9%
2025-09-17188,9560259,13872.9%
2025-09-16203,55446341,72459.6%
2025-09-15274,63530448,71661.2%
2025-09-12212,9184332,54464.0%
2025-09-11387,8134,439687,67356.4%
2025-09-10271,583180472,48457.5%
2025-09-09435,55110,514645,58767.5%
2025-09-08321,931100446,00772.2%
2025-09-05341,7345,833547,12962.5%
2025-09-04381,1280505,16375.4%
2025-09-03545,8963,603690,21679.1%
2025-09-02320,4581,530581,10855.1%
2025-08-29302,5020582,65751.9%
2025-08-28200,7180302,61166.3%
2025-08-27102,469343177,21257.8%
2025-08-26112,4740194,56757.8%
2025-08-25165,2040263,11362.8%
2025-08-22187,7583,090538,67734.9%
2025-08-21185,8541,565714,28426.0%
2025-08-2088,34712180,94748.8%
2025-08-19127,0621,989256,81349.5%
2025-08-1898,4620154,91563.6%
2025-08-15272,2452,909364,11374.8%
2025-08-14195,4155,120386,30750.6%
2025-08-13180,925108441,79841.0%
2025-08-12123,2510304,48140.5%
2025-08-11254,7141,686471,53454.0%
2025-08-08427,52471845,09450.6%
2025-08-07232,9900429,93154.2%
2025-08-06245,049453455,36053.8%
2025-08-05201,4371,908582,44934.6%
2025-08-04105,80412271,83338.9%
2025-08-01189,908631307,78961.7%
2025-07-31156,5220272,30957.5%
2025-07-30177,6080284,86262.3%
2025-07-29186,6501,295330,97456.4%
2025-07-28135,934800165,42782.2%
2025-07-25170,240173313,56454.3%
2025-07-24100,55482184,82354.4%
2025-07-23119,806200158,50575.6%
2025-07-22102,666226190,44753.9%
2025-07-21154,0050288,63153.4%
2025-07-18184,8791,777371,36049.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy